Featured White Papers
- Technology-based learning: Extending reach & ensuring Leadership Development effectiveness (SkillSoft)
- 5 Strategies for Making Sales the Engine for Growth (AchieveGlobal)
- Hosted CRM comparison guide (Inside CRM)
Content provided in partnership with
NHS to offer weight-loss drug despite suicide fears
Independent, The (London), Jun 25, 2008
Home News IN BRIEF
*A controversial weight-loss drug has been approved for use on the NHS. Rimonabant will be made available to overweight or obese patients who cannot take, or who have had no success with, two other drugs, orlistat and sibutramine. It comes after concerns about rimonabant's side effects, including suicidal thoughts and depression. The Medicines and Healthcare Products Regulatory Agency said last month that it had received 720 reports of adverse drug reactions - totalling 2,123 individual reactions - in the UK since the drug was launched in 2006. But the National Institute for Clinical Excellence said: "Being overweight or obese can lead to a range of serious health problems, including heart disease, type-2 diabetes, osteoarthritis and some cancers."
Copyright c 2008 Independent Newspapers UK Limited. All rights
owned or operated by The Independent.
Provided by ProQuest Information and Learning Company. All rights Reserved.
